Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
Rita Assi, Hagop Kantarjian, Michael Keating...
https://pubmed.ncbi.nlm.nih.gov/33283580/Actively Recruiting
Led by M.D. Anderson Cancer Center · Updated on 2026-10-07
3000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are conducting a chart review of patients with Chronic Myelogenous Leukemia CML treated with tyrosine kinase inhibitors TKIs like imatinib, dasatinib, or nilotinib outside of clinical trials. This study focuses on patients seeking a second opinion at M.D. Anderson Cancer Center MDACC to better understand treatment patterns, follow-up, and outcomes in real-world settings. The review addresses gaps in long-term data and treatment adherence compared to clinical trial participants. The study collects detailed information from patient charts, including demographics, lab results, treatment history, dose changes, interruptions, toxicity, and pregnancy outcomes during TKI therapy. Data are gathered from routine care documentation at MDACC and other institutions, without altering treatments. Researchers will analyze this information to compare efficacy, safety, and prognostic markers with those from clinical trials and literature. Participants are not required to undergo any interventions as the study solely reviews existing medical records from July 1998 to August 2019. Researchers will assess responses to standard-dose imatinib and other TKIs, chromosomal abnormalities, and pregnancy outcomes. This observational study continues until April 2030 and involves approximately 3000 patient charts, allowing comprehensive evaluation of real-world treatment experiences and long-term effects.
CONDITIONS
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
K
Koji Sasaki, M.D.
S
Sasaki
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
M.D. Anderson Cancer Center
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Rita Assi, Hagop Kantarjian, Michael Keating...
https://pubmed.ncbi.nlm.nih.gov/33283580/M.D. Anderson Cancer Center
Lead Sponsor